Q-omics provides the consensus-scored H4C7 profile across patient tissues and cancer cell-line models. H4C7 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, H4C7 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, H4C7 RNA expression shows 5,823 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, BRCA, and STAD as cancer lineages where H4C7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H4C7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H4C7 survival associations across molecular data types. H4C7 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H4C7 RNA expression–survival associations across cancer types. High H4C7 expression shows unfavorable associations in THCA, KICH, STAD, DLBC, LUAD and LUSC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for H4C7 RNA expression.
This table summarizes H4C7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for H4C7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H4C7 shows higher tumor expression in BRCA. The BRCA box plot shows higher H4C7 RNA expression in tumor versus normal tissue (log2 FC = +0.023, t-test p = .020).
This table shows molecular features associated with H4C7 in patient tissues and cancer cell lines. In patient samples, H4C7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, H4C7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_NSCLC_LUSC.
